Brokerages Set Alto Neuroscience, Inc. (NYSE:ANRO) PT at $15.40

Shares of Alto Neuroscience, Inc. (NYSE:ANRO) have been given a consensus rating of “Moderate Buy” by the seven ratings firms that are presently covering the firm, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $15.40.

ANRO has been the subject of a number of recent research reports. Wedbush restated a “neutral” rating and issued a $4.00 target price on shares of Alto Neuroscience in a research report on Thursday, May 15th. William Blair restated an “outperform” rating on shares of Alto Neuroscience in a research report on Friday, March 21st. Finally, HC Wainwright initiated coverage on Alto Neuroscience in a research report on Monday, April 7th. They issued a “buy” rating and a $10.00 target price for the company.

Hedge Funds Weigh In On Alto Neuroscience

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Wells Fargo & Company MN raised its holdings in Alto Neuroscience by 40.0% in the fourth quarter. Wells Fargo & Company MN now owns 10,989 shares of the company’s stock worth $46,000 after purchasing an additional 3,139 shares in the last quarter. Deutsche Bank AG increased its stake in shares of Alto Neuroscience by 31.3% in the 4th quarter. Deutsche Bank AG now owns 15,210 shares of the company’s stock worth $64,000 after acquiring an additional 3,629 shares in the last quarter. Rhumbline Advisers increased its stake in shares of Alto Neuroscience by 24.4% in the 4th quarter. Rhumbline Advisers now owns 25,556 shares of the company’s stock worth $108,000 after acquiring an additional 5,008 shares in the last quarter. Bank of New York Mellon Corp lifted its position in Alto Neuroscience by 15.0% during the 4th quarter. Bank of New York Mellon Corp now owns 52,271 shares of the company’s stock valued at $221,000 after acquiring an additional 6,812 shares during the period. Finally, Jane Street Group LLC lifted its position in Alto Neuroscience by 72.0% during the 4th quarter. Jane Street Group LLC now owns 18,600 shares of the company’s stock valued at $79,000 after acquiring an additional 7,783 shares during the period.

Alto Neuroscience Stock Up 8.0%

ANRO stock opened at $2.57 on Wednesday. The company has a quick ratio of 13.09, a current ratio of 13.10 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $69.58 million, a PE ratio of -1.10 and a beta of 1.93. Alto Neuroscience has a twelve month low of $1.60 and a twelve month high of $17.55. The stock has a 50-day simple moving average of $2.38 and a two-hundred day simple moving average of $3.26.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.06. On average, equities analysts predict that Alto Neuroscience will post -2.54 EPS for the current fiscal year.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.